With regard to the choice of bone-protecting agent, denosumab (Xgeva) improved bone density and reduced fracture risk in a ...

During a live event, Jahan Aghalar, MD, discussed the efficacy and safety of darolutamide plus ADT in mHSPC in the ARANOTE ...

Androgen deprivation therapy (ADT) has long been a foundation in the management of prostate cancer. Since the introduction of ...

When standard cancer treatments begin to fail, especially in aggressive or advanced stages, oncologists are increasingly ...

European Union approves Bayer’s Nubeq for patients with advanced prostate cancer: Berlin Tuesday, July 22, 2025, 11:00 Hrs [IST] The European Commission has granted marketing au ...

Berlin: Bayer has received marketing authorization from the European Commission in the European Union (EU) for Nubeqa ...

Pedro C. Barata, MD, MSc, discusses the advantages and disadvantages of darolutamide in metastatic hormone-sensitive prostate ...

The European Commission has granted marketing authorization in the European Union (EU) for German pharma major Bayer’s Nubeqa ...

EEST Darolutamide receives EU approval in third indication for patients with advanced prostate cancer European Commission granted approval ...

Bayer said its Nubeqa treatment was approved by the EU for advanced prostate cancer. The German pharmaceutical and agricultural conglomerate said the European Commission granted approval of Nubeqa in ...

EEST Darolutamide receives EU approval in third indication for patients with advanced prostate cancer European Commission ...

Detailed price information for Bayer Aktienges ADR (BAYRY) from The Globe and Mail including charting and trades.